METHODS
We examined the ex-manufacturer price of Sovaldi (sofosbuvir; Gilead Sciences) and first-generation antivirals Incivek/Incivo (telaprevir; Vertex/J&J) and Victrelis (boceprevir; Merck & Co) in Norway, Denmark, Germany, Luxembourg, Portugal, Slovenia, Turkey, and the United States. Treatment costs were calculated using standard of care protocols for treatment of HCV genotype 1, including individual daily dosage strength and length of recommended treatment for each antiviral. Treatment breakdowns were as follows:
• For sofosbuvir treatment, costs were calculated assuming a daily use for a 400mg strength tablet over a period of 12 weeks
• Telaprevir treatment was calculated as six 375mg tablets daily over a period of 12 weeks
• Boceprevir treatment entailed the administration of 12 200mg strength capsules daily for a period of 24 weeks
Interferon and ribavirin costs, any potential discounts or rebates negotiated with payors, and potential follow-up courses of therapy for sofosbuvir were excluded from the study. Prices were extracted from the IHS Life Sciences international pricing database POLI. All foreign currency was converted to USD using XE Currency Converter for comparison.
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www.ihs.com/LifeSciences Gustav.Ando@ihs.com Table 1 show that costs of treatment with sofosbuvir varied significantly across the eight countries examined. It does not come as a surprise that the highest cost was observed in the United States, where a 12-week course of treatment is around USD84,000. The second-highest treatment cost was calculated for Portugal at USD75,816. Conversely, Norway accounts for the lowest cost of treatment at USD52,051 with sofosbuvir.
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As highlighted in Figure 1 , the average cost of treatment for sofosbuvir across the eight countries is 104% higher on average than a 12-week course of treatment with telaprevir. Similarly, as shown in Figure 2 , a nearly two-fold difference in treatment costs was also observed with sofosbuvir treatment when compared to a 24-week regimen of boceprevir, representing a 187% increase over the boceprevir regimen based on the list price in 2014. Note that for many patients who take Sovaldi, interferon treatment is not required; but for the purposes of this study, this cost factor is excluded. Also note that some patients may need further courses of treatment.
Since it is likely telaprevir and boceprevir have realised notable price changes since their launches in 2011 and 2012 in various markets, we proceeded to draw a comparison between the treatment costs with sofosbuvir and the prices of telaprevir and boceprevir at their respective market launches. We noted that the price of telaprevir dropped in all markets we looked at except the United States, where it realised a 34% increase. The price for boceprevir, by contrast, remained mostly stable since launch with the exception of Germany, where it experienced a 16% drop, and the United States, were the price rose nearly 52%.
The costs of treatment with sofosbuvir were still notably higher than the costs of treatment with telaprevir and boceprevir when factoring in the first-generation antiviral's price at launch instead of 2014. On average, sofosbuvir treatment would be 85% more costly than telaprevir and 190% more costly than treatment with boceprevir.
Furthermore, treatment costs with sofosbuvir were higher than telaprevir and boceprevir in all the countries considered in the study. In 2014, telaprevir and boceprevir treatment costs ranged, respectively, from a low of USD21,534 and USD14,110 in Turkey to a high of USD66,155 and USD40,120 in the United States. (2014) 6816-0914JK
CONCLUSIONS
Our preliminary assessment has highlighted the variable treatment costs of HCV antivirals across countries. The discrepancies across the eight countries considered reflect considerable differences in pricing and reimbursement policies that characterise highly regulated markets compared to free-pricing markets where price regulation plays little or no role. The individual treatment costs of next-generation therapies is demonstrably higher than older therapies; however, treatments such as sofosbuvir are thought to offer some savings on the overall cost to cure HCV compared to older regimens. Separate research is required to look at the broader treatment costs.
Based on the evidence emerging from the data, treatment costs with next-generation therapies will likely significantly increase expenditure on HCV therapeutics over the next few years. Nevertheless, sofosbuvir has demonstrated cure rates of over 90% in genotype 1 HCV patients with a favourable safety profile, so over the long term, new-generation treatments may potentially help reduce costs associated with re-treatment, medical visits, and advanced liver disease, partially offsetting the immediateterm increase in expenditure that will be incurred by global healthcare systems. 
